Imagion Biosystems is pleased to provide an update on its progress and plans for manufacturing of its proprietary nanoparticle formulation in advance of the first in human study currently planned for mid-2020.
Read the update.
Positive independent review sets priority path to market for MagSense® Technology
February 5, 2023
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance